Total Payments
$533,623
2024 Payments
$34,672
Companies
44
Transactions
844
Medicare Patients
594
Medicare Billing
$79,750
Payment Breakdown by Category
Other$405,289 (76.0%)
Travel$78,526 (14.7%)
Consulting$30,235 (5.7%)
Food & Beverage$17,846 (3.3%)
Education$1,727 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $403,301 | 133 | 75.6% |
| Travel and Lodging | $78,526 | 215 | 14.7% |
| Consulting Fee | $30,235 | 22 | 5.7% |
| Food and Beverage | $17,846 | 446 | 3.3% |
| Honoraria | $1,988 | 4 | 0.4% |
| Education | $1,727 | 24 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Seagen Inc. | $137,917 | 141 | $0 (2023) |
| Genentech USA, Inc. | $117,039 | 122 | $0 (2022) |
| Gilead Sciences, Inc. | $91,126 | 98 | $0 (2024) |
| PFIZER INC. | $48,213 | 71 | $0 (2024) |
| Puma Biotechnology, Inc. | $47,397 | 79 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $38,938 | 59 | $0 (2020) |
| Stemline Therapeutics Inc. | $31,562 | 35 | $0 (2024) |
| Amgen Inc. | $6,808 | 36 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $3,329 | 12 | $0 (2024) |
| Astellas Pharma US Inc | $2,634 | 10 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $34,672 | 33 | Gilead Sciences, Inc. ($24,600) |
| 2023 | $79,963 | 93 | Gilead Sciences, Inc. ($31,171) |
| 2022 | $119,326 | 123 | Seagen Inc. ($69,334) |
| 2021 | $58,107 | 70 | Seagen Inc. ($42,990) |
| 2020 | $21,327 | 37 | Genentech USA, Inc. ($5,296) |
| 2019 | $78,271 | 177 | Puma Biotechnology, Inc. ($37,821) |
| 2018 | $52,620 | 159 | Genentech USA, Inc. ($19,948) |
| 2017 | $89,337 | 152 | Genentech USA, Inc. ($49,737) |
All Payment Transactions
844 individual payment records from CMS Open Payments — Page 1 of 34
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | Truqap (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Genentech, Inc. | Itovebi (Biological) | Food and Beverage | In-kind items and services | $75.26 | General |
| Category: BioOncology | ||||||
| 11/21/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,390.00 | General |
| Category: ONC | ||||||
| 11/19/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $1,330.04 | General |
| Category: ONC | ||||||
| 11/19/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $91.02 | General |
| Category: ONC | ||||||
| 11/11/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $6.51 | General |
| 09/24/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 08/23/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,380.00 | General |
| Category: Oncology | ||||||
| 07/09/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $11.88 | General |
| Category: ONCOLOGY | ||||||
| 05/21/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,140.00 | General |
| Category: ONC | ||||||
| 05/03/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,740.00 | General |
| Category: ONC | ||||||
| 04/30/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $1,262.24 | General |
| Category: ONC | ||||||
| 04/30/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $71.54 | General |
| Category: ONC | ||||||
| 04/26/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,300.00 | General |
| Category: Oncology | ||||||
| 04/26/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Travel and Lodging | In-kind items and services | $1,202.77 | General |
| Category: Oncology | ||||||
| 04/20/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $751.20 | General |
| Category: ONC | ||||||
| 04/20/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $500.00 | General |
| Category: ONC | ||||||
| 04/20/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $303.97 | General |
| Category: ONC | ||||||
| 04/20/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $140.00 | General |
| Category: ONC | ||||||
| 04/20/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $57.08 | General |
| Category: ONC | ||||||
| 04/20/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $49.98 | General |
| Category: ONC | ||||||
| 04/20/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $49.98 | General |
| Category: ONC | ||||||
| 04/20/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $24.89 | General |
| Category: ONC | ||||||
| 04/20/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $14.98 | General |
| Category: ONC | ||||||
| 04/19/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONC | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 127 | 238 | $32,015 | $18,255 |
| 2022 | 2 | 150 | 250 | $36,324 | $18,739 |
| 2021 | 2 | 137 | 295 | $39,538 | $21,838 |
| 2020 | 3 | 180 | 321 | $80,290 | $20,917 |
Total Patients
594
Total Services
1,104
Medicare Billing
$79,750
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 111 | 222 | $24,175 | $16,025 | 66.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 16 | 16 | $7,840 | $2,230 | 28.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 131 | 231 | $27,014 | $16,198 | 60.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 19 | 19 | $9,310 | $2,542 | 27.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 123 | 281 | $32,678 | $19,663 | 60.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 14 | 14 | $6,860 | $2,175 | 31.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 146 | 285 | $71,250 | $17,692 | 24.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 16 | 16 | $7,840 | $2,299 | 29.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 18 | 20 | $1,200 | $926.41 | 77.2% |
About Dr. M. Donnelly, M.D
Dr. M. Donnelly, M.D is a Medical Oncology healthcare provider based in Gardner, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/29/2005. The National Provider Identifier (NPI) number assigned to this provider is 1942297528.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. M. Donnelly, M.D has received a total of $533,623 in payments from pharmaceutical and medical device companies, with $34,672 received in 2024. These payments were reported across 844 transactions from 44 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($403,301).
As a Medicare-enrolled provider, Donnelly has provided services to 594 Medicare beneficiaries, totaling 1,104 services with total Medicare billing of $79,750. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Gardner, MA
- Active Since 09/29/2005
- Last Updated 07/08/2007
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1942297528
Products in Payments
- TUKYSA (Drug) $138,964
- Trodelvy (Drug) $89,228
- Perjeta (Biological) $69,907
- Nerlynx (Drug) $45,897
- IBRANCE (Drug) $32,120
- Orserdu (Drug) $31,562
- KISQALI (Drug) $30,267
- Kadcyla (Biological) $24,876
- Herceptin (Biological) $9,466
- PIQRAY (Drug) $8,320
- ORGOVYX (Drug) $8,025
- Phesgo (Biological) $7,070
- TECENTRIQ (Biological) $5,416
- XGEVA (Biological) $4,837
- TALZENNA (Drug) $3,666
- XTANDI (Drug) $2,782
- Xtandi (Drug) $2,353
- ENHERTU (Biological) $1,943
- Cabometyx (Drug) $1,509
- NERLYNX (Drug) $1,500
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.